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Aims Advanced heart failure is often associated with reduced myocardial fatty acid oxidation capacity.
We have previously observed that failing hearts of mice with overexpression of angiotensinogen in the
myocardium exhibit marked reduction of key regulatory proteins of fatty acid oxidation. In the present
study, we determined whether exposure of adult rat cardiac (ARC) myocytes to angiotensin II (Ang II)
influences expression of fatty acid translocase, muscle-type carnitine palmitoyl transferase-I, and
medium-chain acyl-CoA dehydrogenase.
Methods and results Ang II reduced mRNA expression of the three regulatory proteins in ARC myocytes
during the entire 14-days culture period. However, protein expression and palmitate oxidation rate
remained unaltered for 7 days, but subsequently markedly decreased. The decrease of protein
expression and of fatty acid oxidation coincided with the onset of increased protein expression of
tumour necrosis factor-a (TNF-a). The effect of Ang II was completely abolished by either blocking
TNF-a formation through inhibition of reactive oxygen species-mediated activation of nuclear factor-
kB or by neutralizing TNF-a with a specific antibody. Activation of peroxisome proliferator-activated
receptor-a (PPARa) and PPARb/d counteracted Ang II-mediated reduction of the fatty acid oxidation
pathway.
Conclusion Prolonged exposure of cardiac myocytes to Ang II elicits downregulation of the fatty acid
oxidation pathway mediated by enhanced synthesis of TNF-a.
KEYWORDS
Myocytes;
Cell culture;
Energy metabolism;
Angiotensin;
Remodelling
1. Introduction
Cardiac myocytes exposed to chronic stress undergo a
sequence of phenotypic changes, which eventually lead to
heart failure. A number of observations indicate that
adverse ventricular remodelling in response to disease
conditions including myocardial infarction,1,2 pressure3,4 or
volume overload,5 and tachycardia6 is associated with
changes in myocardial energy metabolism.4–8 There is
increasing evidence that fatty acid oxidation is reduced in
advanced stages of ventricular remodelling, and more
glucose is oxidized.7,9 The consequences of reduction of the
fatty acid oxidation pathway for disease progression remain
controversial. On one hand, the shift to glucose oxidation
may protect the myocardium by factors including enhance-
ment of ATP yield per O2 consumed,
10 support of ion pumps
by glycolysis-derived ATP,11 and reduction of proton pro-
duction by oxidation, instead of conversion to lactate, of
glycolytically produced pyruvate.12 On the other hand, a
reduction of fatty acid oxidation may limit overall energy
production and favour accumulation of potentially toxic
lipid intermediates in the cytoplasm (‘lipotoxicity’).13
Reduction of fatty acid oxidation during ventricular remo-
delling and heart failure seems to be mediated by reduction
of protein levels of key regulatory proteins of fatty acid
metabolism.1,6,7,14–16 This has been largely attributed to
inactivation and/or downregulation of the nuclear transcrip-
tion factors peroxisome proliferator-activated receptors
(PPARs) a17,18 and b/d19 or of the PPARg coactivator-1a
(PGC-1a),20 which regulate the expression of multiple
genes controlling both fatty acid uptake and oxidation.
However, a number of observations indicate that, in addition
to reduced transcription, levels of regulatory proteins are
also modulated by posttranscriptional mechanisms. Specifi-
cally, in rodent models of pathological left ventricular remo-
delling, mRNA expression of enzymes of fatty acid oxidation
was reduced during compensated hypertrophy, but protein
expression and fatty acid oxidation rate were maintained
at control levels. However, both protein expression and
fatty acid oxidation dropped dramatically when heart
failure occurred.1,9,14 The signalling pathways driving
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downregulation of the fatty acid oxidation pathway during
ventricular remodelling are largely unknown.
Activation of the renin–angiotensin system and increased
formation of the main effector angiotensin II (Ang II) play a
critical role in left ventricular remodelling and heart
failure.21 Ang II has been implicated in myocyte hypertrophy,
interstitial fibrosis, and apoptosis.22 Furthermore, Ang II
promotes the inflammatory response, which may be involved
in the progression from compensated remodelling to heart
failure.23 However, at present, little is known about
whether Ang II contributes to altered metabolic regulation
in themyocardium undergoing remodelling.We have recently
observed that mice with targeted overexpression of angio-
tensinogen in the myocardium, resulting in chronically elev-
ated myocardial Ang II at unaltered blood pressure,24
progressively develop left ventricular hypertrophy associated
with downregulation ofmRNA expression of a number of regu-
latory proteins of fatty acid oxidation.9 Protein expression
and palmitate oxidation, measured during in vitro perfusion,
did not differ from wild-type mice during compensated
hypertrophy, but were significantly reduced after the onset
of heart failure. Accordingly, chronic stimulation of the myo-
cardium with Ang II elicits progressive myocardial remodel-
ling, which results in reduction of regulatory proteins of the
fatty acid oxidation pathway when heart failure occurs.
However, it is not known whether Ang II stimulation of
cardiac myocytes directly affects expression of the fatty
acid oxidation pathway.
We therefore studied the effects of prolonged stimulation
of adult rat cardiac (ARC) myocytes by Ang II on the
expression of regulatory proteins of fatty acid oxidation.
The results indicate that Ang II elicits downregulation of
the fatty acid oxidation pathway. This effect is largely
mediated by Ang II-induced generation of tumour necrosis
factor-a (TNF-a).
2. Materials and methods
An expanded Materials and methods section is available in the
online data supplement.
The investigation conforms to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of Health
(NIH Publications No. 85-23, revised 1996) and was approved by the
local animal protection authorities.
2.1 Cell isolation and culture
ARC myocytes were isolated from male OFA rats (Charles River,
France) as previously described.25,26 The culture medium was M199
supplemented with 20% (vol/vol) foetal calf serum (FCS; Invitrogen)
throughout the culture period. The culture medium contained
glucose (5.5 mM). Ang II (1–1000 nM), TNF-a (10 ng/mL), N-acetyl
cystein (NAC; 10 mM), apocynin (1 mM), SN50 (18 mM), anti-rat
TNF-a antibody (0.2 mg/mL), WY-14643 (100 nM), L165-041 (1 mM),
or ciglitazone (10 nM) were added to the medium during the
entire culture period. In selected experiments, palmitate plus
oleate (0.05–0.25 mM) at equimolar concentrations complexed to
bovine serum albumin (0.2 mM) were added.
2.2 Immunofluorescence and cell surface area
determination
Cells were fixed with paraformaldehyde and stained (a-actinin,
F-actin, and DNA). Relative cell surface area was calculated from
digitized images.
2.3 [3H]-phenylalanine incorporation
To obtain an index for the rate of de novo protein synthesis,
ARC were incubated with L-[2,3,4,5-3H]-phenylalanine.
[3H]-phenylalanine incorporation was measured, and normalized
to DNA content.
2.4 Measurement of intracellular reactive
oxygen species
Reactive oxygen species (ROS) were measured by the dichlorofluor-
escein fluorescence method. Upon reaction with ROS, DCF becomes
highly fluorescent and fluorescence was then recorded.
2.5 Protein and RNA expression
Western blot and quantitative reverse transcriptase–polymerase
chain reaction were performed as in previous studies.26
2.6 Palmitate oxidation
Palmitate oxidation was estimated based on the release of 14CO2
from [1-14C]-palmitate.26
ARC were incubated in sealed flasks containing a suspended
filter paper and medium containing palmitate (0.05 mM), oleate
(0.05 mM), and 1 mCi/mL [1-14C]-palmitate complexed to bovine
serum albumin (0.2 mM). 14CO2 produced by [1-
14C]-palmitate metab-
olism was collected overnight on the filter paper and quantified.
3. Results
3.1 Ang II and tumour necrosis factor-a elicit
reduction of regulatory proteins of fatty acid
oxidation in adult rat cardiac myocytes
ARC cultured with 20% FCS underwent phenotypic changes
during the 14 days culture period as described previously.26
Three to 4 days after isolation ARC resumed beating, gradu-
ally increased in size, and reexpressed atrial natriuretic
factor (ANF) mRNA. Supplementation of the culture
medium with Ang II (100 nM) significantly enhanced the
hypertrophic response as evidenced by a further increase
of cell size, stimulation of protein synthesis, and increase
of mRNA expression of both ANF and brain natriuretic
peptide (BNP) (Figure 1). Since Ang II stimulates synthesis
of TNF-a,27,28 we exposed, in parallel experiments, cells
to TNF-a (10 ng/mL). TNF-a also increased all indices of
the hypertrophic response, even more pronounced in
extent compared with Ang II (Figure 1).
To determine the effects of both Ang II and TNF-a on key
regulatory proteins of the fatty acid oxidation pathway, we
monitored expression of fatty acid translocase (FAT/CD36),
muscle-type carnitine palmitoyl transferase-I (mCPT-I) and
medium-chain acyl-CoA dehydrogenase (MCAD). Protein
expression of all three regulatory proteins remained stable
in control ARC during the 14 days culture period. Both Ang
II and TNF-a elicited a gradual reduction of the three regu-
latory proteins (Figure 2A–C). However, there was a clear
difference in the time-course. Supplementation of the
medium with Ang II during the entire culture period did
not affect protein expression up to day 7. Thereafter,
protein expression decreased to reach 60% of control on
day 14. The reduction of protein expression by Ang II was
concentration-dependent (Supplementary material online,
Figure S2). In contrast to Ang II, TNF-a more rapidly
reduced protein expression of FAT/CD36, mCPT-I, and
MCAD, starting from the onset of the culture period, to
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levels as low as 10% of control after 14 days (Figure 2A–C).
Correspondingly, exposure of ARC to TNF-a for 7 days
reduced palmitate oxidation (to 30%), whereas Ang II had
no effect (Figure 2G). During exposure for more than 7
days both TNF-a and Ang II reduced palmitate oxidation
(to 15% and 41%, respectively, after 14 days).
In contrast to protein expression, mRNA expression of
FAT/CD36, mCPT-I, and MCAD rapidly decreased after iso-
lation in untreated control ARC to 40 to 60% of values
measured in freshly isolated cells (Figure 2D–F). Both Ang
II and TNF-a elicited a further reduction of mRNA expression
of all three regulatory proteins compared with untreated
ARC. We have previously observed that the reduction of
mRNA expression in control experiments is related to the
low fatty acid concentration in the standard culture
medium since it is prevented by the addition of fatty acid
to the culture medium.26
To determine the role of the high concentration of FCS in
the effects of Ang II, in additional experiments, ARC cul-
tured in medium containing a low concentration of FCS
(1%) were exposed to Ang II (100 nM) or TNF-a (10 ng/mL)
for up to 7 days. Both Ang II and TNF-a reduced regulatory
proteins of fatty acid oxidation and palmitate oxidation to
a similar extent compared with results obtained in the pre-
sence of 20% FCS. However, Ang II-induced reduction of both
protein expression and palmitate oxidation was detectable
earlier, already on day 4, and was reduced on day 7 to
values comparable to those observed in the presence of
20% FCS on day 14. The decrease of both regulatory proteins
and palmitate oxidation by TNF-a was also accelerated
compared to experiments in ARC cultured with 20% FCS
(Supplementary material online, Figure S3).
3.2 Ang II-induced reduction of the fatty acid
oxidation pathway involves ROS-dependent
activation of NF-kB
Because nuclear factor-kB (NF-kB) plays a central role in the
Ang II-mediated hypertrophic response,29 we first measured
phosphorylation of the p65 subunit of NF-kB at ser536,
which is a marker of NF-kB activation.30 Total NF-kB protein
level was not altered by Ang II (data not shown). However,
phosphorylation of NF-kB progressively and concentration-
dependently increased in the presence of Ang II until day 10
and then levelled off or slightly decreased (Figure 3A). Ang
II at a concentration of 100 nM elicited a maximal response.
The Ang II-induced increase of phospho-NF-kB was completely
abolished if accumulation of ROS was prevented either by the
NADPH oxidase inhibitor apocynin or the ROS scavenger NAC
(Figure 3B). Prevention of ROS accumulation was validated
in separate experiments by monitoring of dichlorofluorescin
diacetate fluorescence (data not shown). Of note, TNF-a, in
the absence of Ang II, rapidly and markedly enhanced
phosphorylation of NF-kB (Figure 3A).
Inhibition of Ang II-induced ROS activity by apocynin or
NAC completely prevented the reduction of protein
expression of FAT/CD36, mCPT-I, and MCAD (Figure 3D),
and the decrease of palmitate oxidation (Figure 3E).
Reduction of both expression of regulatory proteins and pal-
mitate oxidation rate was also prevented by SN50 (Figure 3D
and E) which inhibits translocation of NF-kB to the nucleus,
Figure 1 Ang II and tumour necrosis factor-a (TNF-a) increase indices of myocyte hypertrophy in adult rat cardiac (ARC). (A) Relative difference of ARC size
measured after 14 days of culture in control medium or medium supplemented with either Ang II (100 nM) or TNF-a (10 ng/mL). Cells were stained for a-actinin
(green), F-actin (red) and DNA (blue). At least 100 cells in different cultures were measured for each condition. (B) De novo protein synthesis, estimated from
[3H]-phenylalanine incorporation. (C and D) mRNA expression of ANF (C) or brain natriuretic peptide (D). n ¼ 4–8. Values are means+ SEM. *P , 0.05 compared
with control.
Ang II-mediated reduction of fatty acid oxidation 343
without affecting phosphorylation (Figure 3B). Thus, ROS-
mediated activation and translocation of NF-kB is necessary
for Ang II-mediated downregulation of the fatty acid oxi-
dation pathway.
3.3 Production of tumour necrosis factor-a
mediates Ang II-induced reduction of the fatty
acid oxidation pathway
To determine the role of TNF-a in Ang II-induced downregu-
lation of regulatory proteins of fatty acid oxidation, we first
measured the effect of Ang II on TNF-a expression in ARC.
Ang II concentration-dependently stimulated protein
expression of TNF-a (Figure 3F). However, TNF-a expression
was absent or low during the first 7 days at Ang II concen-
trations up to 100 nM. Induction of TNF-a protein expression
was completely abolished by NAC, apocynin, and SN50 indi-
cating the involvement of the ROS–NF-kB cascade in the
stimulation of TNF-a expression (Figure 3G).
To further evaluate whether TNF-a secreted by ARC in
response to Ang II stimulation was sufficient to reduce the
fatty acid oxidation pathway, we added an antigen-affinity
purified polyclonal rabbit anti-rat TNF-a antibody (0.2 mg/
mL) to the culture medium. Anti-TNF-a had no effect in
unstimulated control cells (data not shown), but completely
prevented the Ang II-induced reduction of regulatory pro-
teins of fatty acid oxidation (Figure 4A) and of palmitate
oxidation rate (Figure 4B). Interestingly, anti-TNF-a mark-
edly reduced Ang II-induced phosphorylation of NF-kB in
ARC later than 7 days after isolation, suggesting that the
generation of TNF-a largely mediated phosphorylation of
NF-kB during the second week of culture (Figure 3C). Collec-
tively, these data indicate that downregulation of the fatty
acid oxidation pathway in ARC exposed to Ang II is mediated
by TNF-a.
3.4 Ang II reduces protein expression of PPARa,
PPARb/d, and PPARg via tumour necrosis factor-a
Because several previous studies have implicated
reduction of transcriptional activity of PPARa17,18 and
PPARb/d19 in the downregulation of the fatty acid oxi-
dation pathway during myocardial hypertrophy and heart
failure, we next evaluated the effect of Ang II on the
expression of three PPAR isoforms PPARa, PPARb/d, and
PPARg. In control ARC, protein expression of PPARs did
not appreciably change during the 14 days culture period
(Figures 5A–C).
Ang II elicited a modest, dose-dependent, reduction of
protein expression of PPARa, PPARb/d, and PPARg
(Figures 5A–C; Supplementary material online, Figure S2)
on day 14. Interestingly, during the first 5 to 7 days of
culture expression of PPAR proteins was even slightly
higher in ARC exposed to Ang II than in control ARC. In
Figure 2 Both Ang II and tumour necrosis factor-a (TNF-a) reduce expression of key regulatory proteins of fatty acid oxidation, but with different time-course.
(A–C) Time-course of protein expression of FAT/CD36 (A), mCPT-I (B), and MCAD (C) in control adult rat cardiac (ARC) (open squares), ARC exposed to Ang II (filled
squares), or ARC exposed to TNF-a (filled circles) during the 14-day culture period. (D–F) mRNA expression of FAT/CD36 (D), mCPT-I (E), and MCAD (F). Values in
(A) to (F) are expressed as percentage of values measured in freshly isolated ARC. (G) Oxidation of [14C]-palmitate measured after different culture intervals in
control ARC (open bars), ARC exposed to Ang II (black bars), or ARC exposed to TNF-a (hatched bars). n, at least three determinations for each culture interval
and each condition. Values are means+ SEM. *P , 0.05 compared with control.
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contrast to Ang II, TNF-a markedly reduced protein
expression of the three PPAR isoforms during the entire
culture period (Figures 5A–C).
In ARC exposed to Ang II, the addition of anti-TNF-a anti-
bodies, or blocking of TNF-a synthesis by apocynin, NAC, or
SN50, prevented the late decrease of PPARa, PPARb/d, and
Figure 3 Ang II elicits phosphorylation of NF-kB, downregulation of the fatty acid oxidation pathway, and enhancement of expression of TNF-a in a ROS-
dependent manner. (A) Time-course of Ang II- and TNF-a-mediated phosphorylation of the p65 subunit of NF-kB at ser536. (B) Inhibition of ROS accumulation
by either NAC or apocynin-blocked phosphorylation of NF-kB. (C) Binding of TNF-a by an antibody reduced NF-kB phosphorylation during the second week of
culture. (D) Inhibition of ROS accumulation by either NAC or apocynin, or inhibition of translocation of NF-kB by SN50 prevented Ang II-mediated reduction
of protein expression of FAT/CD36 (open bars), mCPT-I (filled bars), and MCAD (hatched bars). (E) The same interventions also prevented reduction of palmitate
oxidation (shown are measurements on day 14). (F) Ang II dose-and time-dependently stimulated protein expression of TNF-a in ARC. (G) Inhibition of ROS
accumulation or blockade of NF-kB translocation by SN50 abolished Ang II-mediated synthesis of TNF-a. n, at least three determinations for each culture interval
and each condition (F and G). All values are means+ SEM. *P , 0.05 compared with control (14 days), †P , 0.05 compared with Ang II alone.
Figure 4 Neutralization of TNF-a by an antibody prevents downregulation of regulatory proteins of fatty acid oxidation. (A) Ang II-induced reduction of protein
expression of FAT/CD36, mCPT-I, and MCAD was completely abolished by addition of anti-TNF-a antibodies to the culture medium during the entire culture period
(shown is protein expression on day 14). (B) Reduction of palmitate oxidation was abolished by anti TNF-a (values of day 14). n, at least four determinations for
each culture interval and each condition. Values are means+ SEM. *P , 0.05 compared with control, †P , 0.05 compared with Ang II alone.
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PPARg proteins (Figure 5D). Collectively, the results suggest
that protein expression of PPARs is reduced during prolonged
exposure to Ang II by release of TNF-a, analogous to obser-
vations on FAT/CD36, mCPT-I, and MCAD. Ang II itself seems
rather to enhance protein expression of PPARs and counter-
act the effect of TNF-a.
3.5 Activation of PPARa and PPARb/d attenuates
the effects of Ang II on the fatty acid
oxidation pathway
To determine whether ligand-mediated activation of PPARs
influences Ang II-induced downregulation of the fatty acid
oxidation pathway, we first examined the effect of sup-
plementation of the culture medium with fatty acid.26 In
ARC exposed to Ang II (100 nM) supplementation of the
medium with fatty acid, concentration-dependently atte-
nuated the reduction of PPAR protein expression (Sup-
plementary material online, Figure S4). The addition of
0.5 mM fatty acid (0.25 mM palmitate plus 0.25 mM
oleate) completely prevented the Ang II-induced reduction
of protein expression of all three PPAR isoforms (Sup-
plementary material online, Figure S4). Fatty acid also pre-
vented the reduction of protein expression of FAT/CD36,
MCAD, and mCPT-I concentration-dependently (Figure 6A;
Supplementary material online, Figure S4), while mRNA
expression of regulatory proteins was increased four- to
five-fold compared with ARC exposed to Ang II alone
(Figure 6B).
To identify the role of individual PPAR isoforms, we sup-
plemented the culture medium with specific agonists of
either PPARa (WY-14643), PPARb/d (L165-041) or PPARg
(ciglitazone) in fatty acid-free standard medium. Specificity
of these ligands has been shown previously.26
Activation of either PPARa by WY-14643 or of PPARb/d by
L165-041 partially restored protein expression of FAT/CD36,
mCPT-I, and MCAD, while combined stimulation of both iso-
forms completely restored protein expression (Figure 6A).
mRNA expression was concomitantly increased 4- to
10-fold to values exceeding those measured in untreated
control ARC (Figure 6B). In contrast, activation of PPARg
by ciglitazone had no effect on mRNA and protein expression
of fatty acid oxidation genes. Neither fatty acid nor specific
agonists prevented Ang II-mediated phosphorylation of
NF-kB and enhancement of TNF-a protein expression
(Figure 6C and D). The results indicate that combined acti-
vation of PPARa and PPARb/d counteracts downregulation
the fatty acid oxidation pathway by Ang II, independently
of TNF-a synthesis, most likely by the stimulation of tran-
scription of regulatory proteins of fatty acid oxidation.
3.6 Effect of inhibition Ang II-mediated generation
of tumour necrosis factor-a and activation of PPARs
on morphology and brain natriuretic peptide
expression of adult rat cardiac
In Ang II-treated ARC, scavenging of ROS by NAC, inhibition
of NF-kB translocation to the nucleus by SN50, or binding
Figure 5 Effect of Ang II and TNF-a on protein expression of PPARa (A), PPARb/d (B), and PPARg (C). n, at least three determinations for each culture interval
and each condition. (D) Inhibition of ROS accumulation by NAC or apocynin, blockade of nuclear translocation of NF-kB by SN50, or addition of anti-TNF-a anti-
bodies prevented downregulation of all three PPAR isoforms (day 14 of culture). n, at least four determinations for each condition. Values are means+ SEM. *P ,
0.05 compared with control.
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of TNF-a by anti-TNF-a antibodies reduced cell surface and
BNP mRNA to values comparable to untreated control ARC
(Supplementary material online, Figure S5). Thus, interven-
tions that prevent Ang II-mediated downregulation of the
fatty acid oxidation pathway by inhibition of TNF-a
expression also attenuate the hypertrophic response and
BNP expression (Supplementary material online, Figure S5).
On the other hand, selective activation of PPARa and
PPARb/d, which prevent reduction of regulatory proteins
of fatty acid oxidation, had no effect on cell size and BNP
mRNA. However, selective activation of PPARg and non-
selective activation of all PPAR isoforms by fatty acids pre-
vented the increase in cell surface area and upregulation
of mRNA expression of BNP and ANF (Supplementary
material online, Figures S4 and S5) in ARC exposed to Ang
II. Thus, in our study activity of PPARg, but not activity of
PPARa and PPARb/d seem to modulate the hypertrophic phe-
notype induced by Ang II.
4. Discussion
Ang II has been ascribed a central role in the phenotype
modification of cardiac myocytes during pathological ventri-
cular remodelling and heart failure. We have previously
reported that failing hearts of mice with targeted overex-
pression of angiotensinogen in the myocardium exhibited
marked downregulation of fatty acid oxidation enzymes.9
Our present study indicates that prolonged exposure of
ARC myocytes to Ang II is sufficient to reduce expression of
key regulatory proteins of fatty acid oxidation including
FAT/CD36, mCPT-I, and MCAD. This effect of Ang II on meta-
bolic regulation is generated indirectly by stimulation of
synthesis of TNF-a in the cardiac myocytes in response to
ROS-induced activation of NF-kB.
The involvement of TNF-a in Ang II-mediated downregula-
tion of the fatty acid oxidation pathway is supported by at
least three observations of the present study: first, the
onset of downregulation of regulatory proteins of fatty
acid oxidation coincides with the onset of Ang II-induced
generation of TNF-a. Second, the addition of TNF-a to the
culture medium resulted in rapid reduction of protein
expression of regulatory proteins of fatty acid oxidation.
Third, addition of anti-TNF-a antibodies to Ang II-stimulated
ARC completely blocked the effect of Ang II on the fatty acid
oxidation pathway. To date, very little is known on the
effects of TNF-a on metabolic regulation in the myocar-
dium. Consistent with our results, Sekiguchi et al.31 have
observed in 8-week-old mice with cardiac-restricted overex-
pression of TNF-a that mRNA expression of FAT, mCPT-I, and
very long-chain acyl-CoA dehydrogenase was reduced.
Although protein expression has not been reported in their
study, palmitate oxidation, measured in myocardial hom-
ogenate, was reduced, compatible with concomitant
reduction of regulatory proteins.
Previous studies have demonstrated that TNF-a biosyn-
thesis is stimulated in cardiac myocytes in response to Ang
II.27 In contrast to observations in adult feline cardiac myo-
cytes cultured in serum-free medium,27 we did not detect
expression of TNF-a in ARC for 3 to 10 days after the onset
of exposure to Ang II. The time-delay was dose-dependent
and decreased with increasing concentration of Ang II. It
needs to be emphasized that in the present study ARC
were cultured with 20% FCS, which may alter the cellular
response to Ang II. Using this culture condition, ARC
undergo during the first 2 to 3 days a process of dedifferen-
tiation with phenotypic changes, which include disassembly
of the contractile elements,32 followed by redifferentiation
with resumption of contraction between day 4 and 7.33 Ang II
Figure 6 Activation of PPARa and PPARb/d, but not of PPARg, increased protein and mRNA expression of regulatory proteins of fatty acid oxidation without
reduction of TNF-a. (A) Supplementation of the culture medium with fatty acid (FA; 50% palmitate/50% oleate) or with specific ligands of PPARa (WY14643)
or PPARb/d (L165-041) increased protein expression of FAT/CD36 (open bars), mCPT-I (hatched bars), and MCAD (filled bars). Activation of PPARg by ciglitazone
had little effect. (B) Fatty acid, WY14643, and L165-041 markedly increased mRNA expression of regulatory proteins to levels exceeding control. (C and D) Acti-
vation of PPARs did neither reduce Ang II-mediated phosphorylation of NF-kB (C), nor induction of TNF-a protein expression (D). Data of all panels were measured
on day 14. n, at least four determinations for each condition. Values are means+ SEM. *P , 0.05 compared with control.
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signalling was not abrogated during the first week of culture,
since Ang II-mediated phosphorylation of NF-kB and stimu-
lation of protein synthesis were not abolished. Reduction
of FCS to 1% shortened the time-delay of Ang II-induced
reduction of regulatory proteins of fatty acid oxidation and
palmitate oxidation rate, indicating that some component(s)
of the serum may protect fatty acid oxidation from Ang
II-induced downregulation. The mechanism remains
unknown. Noteworthy, reduction of FCS to 1% did neither
alter the ultimate extent of reduction of regulatory proteins
of fatty acid oxidation and palmitate oxidation rate, nor the
reversal by anti-TNF-a antibodies. Therefore, the concen-
tration of FCS seems not critical for the ultimate effects
of Ang II on the fatty acid oxidation pathway.
Consistent with observations in neonatal rat cardiac myo-
cytes,19 our results suggest a central role of activation of
NF-kB in downregulation of the fatty acid oxidation
pathway. Inhibition of Ang II-mediated activation or translo-
cation of NF-kB by apocynin, NAC or SN50 completely pre-
vented reduction of regulatory proteins of fatty acid
oxidation. NF-kB has been proposed to lower fatty acid oxi-
dation by direct interaction with PPARs which regulate tran-
scription of target genes involved in fatty acid oxidation
(transrepression).19
NF-kB is activated by receptor-initiated signalling cas-
cades of both Ang II, via the AT-1 receptor,34 and TNF-a,
via TNF-a receptor 1.35 Furthermore, Ang II-induced acti-
vation of NF-kB stimulates TNF-a synthesis in adult
cardiac myocytes,27 which may greatly amplify activation
of NF-kB during exposure to Ang II. In fact, in our exper-
iments, inactivation of TNF-a by anti-TNF-a antibodies
did not diminish Ang II-induced phosphorylation of NF-kB
on days 1 and 3, but markedly attenuated NF-kB phos-
phorylation on day 7 and later, indicating a predominant
role of TNF-a in NF-kB activation during the second week
of culture. The finding that inactivation of TNF-a by
anti-TNF-a antibodies prevents downregulation of the
fatty acid oxidation pathway suggests that activation of
NF-kB by Ang II alone is sufficient to trigger synthesis of
TNF-a, but insufficient to reduce levels of regulatory pro-
teins of fatty acid oxidation. The cellular mechanism
underlying the necessity of TNF-a for downregulation of
the fatty acid oxidation pathway is open to speculation.
On one hand, activation of NF-kB by stimulation of the
AT-1 receptor alone may be quantitatively insufficient. In
fact, TNF-a-independent activation of NF-kB by Ang II, esti-
mated during inhibition of TNF-a by antibodies, was mark-
edly lower compared with activation without TNF-a
inhibition. On the other hand, downregulation of regulatory
proteins of fatty acid metabolism may be mediated by
NF-kB-independent signals triggered by TNF-a.
Considerable evidence implicates reduction of transcrip-
tional activity of PPARa and/or PPARb/d in the downregula-
tion of the fatty acid oxidation pathway during progression
of maladaptive myocardial remodelling.19 Both PPARa and
PPARb/d are involved in the regulation of transcriptional
activity of genes encoding regulatory proteins of fatty acid
metabolism, including FAT/CD36, mCPT-I, and MCAD. Pro-
posed mechanisms for inactivation of transcriptional activity
of PPARa, which is best characterized as yet, include
reduced expression of PPARs,17 posttranslational inacti-
vation by Erk1/2-mediated phosphorylation,17 reduced
availability of cofactors including PGC-1,36 and increased
expression of the repressor protein chicken ovalbumin
upstream promoter transcription factor.18 Finally, transcrip-
tional activity may be reduced by transrepression by nuclear
transcription factors including NF-kB and activator protein-1
(AP-1), as has been shown in phenylephrine-stimulated neo-
natal rat cardiac myocytes for PPARb/d.19
In our study, mRNA expression of FAT/CD36, mCPT-I, and
MCAD was reduced by Ang II in ARC after 3 days of culture,
indirectly suggesting that the transcription was decreased
early during exposure to Ang II. Since protein expression of
all three PPAR isoforms was decreased only during the
second week of exposure to Ang II, the results are compati-
ble with the interpretation that inactivation of PPARs pre-
ceded reduction of PPAR protein expression.17,18,36 Despite
early reduction of mRNA expression of FAT/CD36, mCPT-I,
and MCAD, protein expression was maintained for several
days and dropped only during the second week of culture,
when TNF-a was generated. Therefore, it is likely that post-
transcriptional mechanisms are critically involved in the
regulation of protein expression of FAT/CD36, mCPT-I, and
MCAD in ARC and the reduction in response to Ang II. The
mechanism of presumed posttranscriptional reduction of
regulatory proteins of fatty acid oxidation by TNF-a is not
known. However, there is evidence suggesting that TNF-a
may enhance degradation of selected proteins by the
ubiquitin-proteasome pathway.37
We have previously observed a similar dissociation between
myocardial mRNA and protein expression of regulatory pro-
teins of fatty acid metabolism in mice with targeted over-
expression of angiotensinogen in the myocardium.9 mRNA
expression of mCPT-I and MCAD progressively decreased
during compensated hypertrophy, whereas protein expression
did not change. However, protein expression and palmitate
oxidation, measured during isolated heart perfusion in
vitro, markedly dropped after the onset of heart failure. A
similar observation has been reported by Sack et al.14 in spon-
taneously hypertensive SHHR/Mcc-facp rats. Although myo-
cardial TNF-a content has not been measured in these
in vivo studies, our results raise the possibility that the
reduction of protein expression of regulatory proteins of
fatty acid oxidation and consecutive reduction of metabolic
flux may be related to enhanced exposure of the myocardium
to TNF-a.38
Although our data indirectly suggest the involvement of
posttranslational mechanisms, the results clearly indicate
that PPAR activity critically influences both the hypertrophic
response and expression of regulatory proteins of fatty acid
oxidation in ARC exposed to Ang II. Supplementation of the
culture medium with 0.5 mM fatty acid (50% oleate/50% pal-
mitate) and selective activation of PPARa and PPARb/d, but
not activation of PPARg, restored mRNA and protein
expression of regulatory proteins of fatty acid metabolism,
and prevented reduction of palmitate oxidation rate.
Activation of PPARa and PPARb/d may prevent reduction
of regulatory proteins of fatty acid oxidation by at least
two different mechanisms. The first mechanism is direct
stimulation of transcription of target genes by binding to
peroxisome proliferator responsive elements in the promo-
ter region. Consistent with this possibility, mRNA expression
of regulatory genes of fatty acid metabolism was increased
4- to 10-fold concomitantly with the restoration of protein
expression. The second mechanism is direct interaction
with transcription factors that are involved in the
C. Pellieux et al.348
hypertrophic response, including NF-kB and AP-1, which
potentially may, directly or indirectly, contribute to
reduction of proteins of fatty acid oxidation.39 Consistent
with this concept, some studies have provided evidence
that PPARa reduces TNF-a in the myocardium exposed to
hypertrophic40 or inflammatory stimuli,41 apparently by
inhibition of NF-kB.41 However, in our study, we did not
observe a reduction of TNF-a during specific or non-specific
stimulation of either PPAR isoform in ARC exposed to Ang II.
Therefore, our observations are more consistent with the
interpretation that stimulation of transcription during acti-
vation of PPARa and PPARb/d compensated for both tran-
scriptional and posttranscriptional reduction of regulatory
proteins of fatty acid oxidation. This mechanism of restor-
ation of regulatory proteins of fatty acid metabolism
differs from that effective during restoration of the fatty
acid oxidation pathway by NAC, apocynin, or SN50, which
all reduced synthesis of TNF-a by prevention of activation
and nuclear translocation of NF-kB.
In summary, the findings of this study demonstrate for the
first time that prolonged exposure of cardiac myocytes to
Ang II may alter substrate metabolism in cardiac myocytes,
characterized by reduction of the fatty acid oxidation
capacity. The effect is largely mediated by the inflammatory
cytokine TNF-a. The observation may be relevant for the
understanding of the cellular mechanisms underlying the
shift from fatty acid to glucose metabolism observed in
the myocardium under conditions of ventricular remodelling
and heart failure.7,9,10,14 A critical question remains
whether limitation of fatty acid oxidation is an adaptive
response or may contribute to further damage of the
myocardium.
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